Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity[1].
| Animal Model: | NOD SCID or RAG mice injected with 1×106 SKOV3 ovarian cancer cells[1]. |
| Dosage: | 100 mg/kg. |
| Administration: | Oral administration daily for about 60 days. |
| Result: | Robustly suppressed tumor growth and progression. |
